Exact Sciences Corp (MIL:1EXAS) Share Price

Company Profile

Business description
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Contact
5505 Endeavor Lane
MadisonWI53719
USA
T: +1 608 284-5700
E: [email protected]
https://www.exactsciences.com
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
7,000

Recommended

We were wrong when we thought last quarter would be hard to top.

Dan Romanoff, CPA | 31 July 2025

These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.

Susan Dziubinski | 30 July 2025

We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.

Shaun Ler | 30 July 2025

Index	Last price	Change	% Change
All Ordinaries	8,917.10	81.90	-0.91%
CAC 40	7,546.16	225.81	-2.91%
DAX 40	23,425.97	639.50	-2.66%
Dow JONES (US)	43,588.58	542.40	-1.23%
FTSE 100	9,068.58	64.23	-0.70%
HKSE	24,507.81	265.52	-1.07%
NASDAQ	20,650.13	472.31	-2.24%
Nikkei 225	40,799.60	270.22	-0.66%
NZX 50 Index	12,729.40	94.34	-0.74%
S&P 500	6,238.01	101.38	-1.60%
S&P/ASX 200	8,662.00	80.80	-0.92%
SSE Composite Index	3,559.95	13.26	-0.37%